Publications by authors named "Shikha Walia"

4 Publications

  • Page 1 of 1

Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris.

J Dermatolog Treat 2021 Jan 12:1-3. Epub 2021 Jan 12.

Dermatology Research and Education Foundation, Irvine, CA, USA.

The occurrence of the COVID-19 pandemic has raised new uncertainties for dermatologists and their patients, importantly concerning initiation and continuation of immunosuppressants for dermatological conditions at this time. We review two phase III trials of rituximab, a chimeric CD20 monoclonal antibody, used for the treatment of pemphigus vulgaris. Without specific data studying rituximab use and susceptibility of SARS-CoV-2, we hope to utilize available data in order to assist clinician decision making for rituximab in the context of the pandemic.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1870648DOI Listing
January 2021

Management of psoriasis with biologics in clinical practice: an update for 2020.

Cutis 2020 Aug;106(2S):21-24

Dermatology Research and Education Foundation, Irvine, California, USA.

This article aims to address updates on recent clinical trial findings (April 2019 to April 2020) regarding biologic therapy initiation and maintenance for adult patients. Prescribers should use this update as guidance for determining the appropriate biologic class based on patient characteristics and for approaching biologic-experienced patients with refractory psoriasis. This update also may serve as a reference for the recommended dosing regimens of the 11 approved biologics.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.12788/cutis.0035DOI Listing
August 2020

Skin cancer screening and prevention during the COVID-19 pandemic.

Cutis 2021 01;107(1):41-42;53

Dermatology Research and Education Foundation, Irvine, California, USA.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.12788/cutis.0157DOI Listing
January 2021

Postnatal outcome of prenatally diagnosed severe fetal renal pelvic dilatation.

Prenat Diagn 2012 Jun 9;32(6):519-22. Epub 2012 May 9.

Centre for Fetal Care, Queen Charlotte's and Chelsea Hospital, Imperial College London, London, W12 0HS, UK.

Objective: We correlated the prenatal severity with the postnatal outcome of prenatally detected renal pelvic dilatation (RPD).

Methods: Cases of prenatally detected RPD referred between January 2002 and December 2008 were included. Severe RPD was defined as an anterior-posterior diameter of 15 mm, mild and moderate dilatation was defined as 6 to <10 mm and 10 to <15 mm, respectively. Postnatal diagnosis, the need for surgery and the correlation with the prenatal severity was ascertained.

Results: Of the 762 patients with RPD, 492 (64.5%) were mild, 167 (21.9%) were moderate, and 103 (13.5%) were severe. The male:female ratio for the severe cohort was 5:1. Of the sever cases, 68% had progressive dilatation. Of the mild/moderate cases, 5% progressed to severe dilatation. PUJ obstruction was confirmed in 48 cases (60.8%), severe VUR in 11 cases (14%), VUJ obstruction in 5 cases (6%), PUV in 2 cases (2.5%), and a nonidentifiable cause in 13 cases (16.5%). Ten of the 48 (20.8%) babies with PUJ obstruction required surgery within the first year of life.

Conclusion: An obstructive cause is usually present in severe cases, which are more likely to require surgery if there is PUJ obstruction. A high male:female ratio was present in this group.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1002/pd.2893DOI Listing
June 2012